Improving cancer care access and outcomes through patient navigation
Official title: PARTNERS: Promoting Access, Resources and Treatment Through Novel and Equitable Solutions for Cancer Care
Run by Case Comprehensive Cancer Center · NCT06481774 · Data updated 2026-11-12
This study tests a new way to help people newly diagnosed with cancer get better access to care and support, especially for those who might not have the same resources.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 375 (estimated) |
| Sponsor | Case Comprehensive Cancer Center Academic / other |
| Locations | 1 site (Cleveland, Ohio) |
| Status | Recruiting |
| Started | July 30, 2024 |
| Main results expected | June 30, 2027 |
| Study ends | June 30, 2027 |
| Registry record updated | November 4, 2026 |
| Trial ID | NCT06481774 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals who have had a suspicious cancer screening finding or are referred to a diagnostic clinic, particularly those identifying as African American, Hispanic, or residing in high-need geographic areas.
✕Probably not a fit
Patients who do not have a suspicious cancer screening finding or are not willing to complete an informed consent form may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This research evaluates a novel approach to providing patient navigation services aimed at enhancing cancer outcomes and quality of life for individuals newly diagnosed with cancer. The study focuses on integrating navigational processes to ensure timely and equitable access to cancer care, particularly for underserved populations. By leveraging the CONNECT platform, the initiative seeks to address disparities in cancer service delivery based on social determinants of health. The study is part of a national effort to create a sustainable model for equitable cancer care services.
Why it matters
Potential benefit: If successful, this initiative could significantly improve cancer care access and outcomes for underserved populations.
How similar studies have gone: Other studies have shown success with patient navigation approaches in improving cancer care access and outcomes, making this initiative a continuation of established practices.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: There are two levels of criteria for inclusion. * First, investigators will identify individuals who have either had a cancer screening with a suspicious finding (ie. requires diagnostic follow-up) or those individuals who are referred to the UH Seidman Diagnostic Clinic (led by Co-I Hoehn). * Within that group, investigators will recruit those who identify as African American, Hispanic, or living in a prioritized geography as defined by zip code ADI\>=75%ile for state Exclusion Criteria: * Any participant who is not willing or able to complete an informed consent form will not be eligible for this study
Where it's running
-
Case Comprehensive Cancer Center
Cleveland, Ohio, United States Recruiting
Study contacts
- Principal investigator: Erika Trapl, PhD — Case Western Reserve University, Case Comprehensive Cancer Center
- Study coordinator: Erika Trapl, PhD
- Email: erika.trapl@case.edu
- Phone: 216-368-0098
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Robot-assisted bronchoscopy for peripheral lung lesions: comparing Monarch and ION platforms
Doctors are testing two FDA-cleared robotic bronchoscopy tools to see which more often successfully sample peripheral lung lesions during a bronchoscopy.
-
Safety and preliminary activity of BMS-986504 in unresectable MPNST
A new medicine called BMS-986504 is being tested to see if it is safe and may help people with unresectable malignant peripheral nerve sheath tumors, especially those whose tumors lack MTAP.
-
Wearable sensors and digital health in early cancer trials
This pilot study tests whether wearable activity tracking and electronic patient-reported outcomes can be feasibly used in early-phase cancer trials for adults.
-
HPV DNA-guided chemoradiation with Retifanlimab for locally advanced anal cancer
This study tests whether adjusting chemoradiation doses based on HPV ctDNA results and adding Retifanlimab after CRT can improve outcomes for adults with new, locally advanced anal cancer.
-
MiraBurst to help with changes in taste from cancer treatment
This study tests whether freeze-dried miracle fruit (MiraBurst) can improve taste changes in adults with solid tumors who are undergoing cancer treatment.
-
Memory-avoidance whole brain radiotherapy: trying to protect memory while treating brain metastases
This study tests whether memory-avoidance whole brain radiotherapy with memantine is better at preserving thinking and memory than hippocampal-avoidance whole brain radiotherapy with memantine for adults with brain metastases.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.